The deal, effective immediately and valid until August 31, 2017, covers the Sysmex XS-1000i, Sysmex pocH-100i, Sysmex XP-300, XT-Series and XN-Series automated haematology analysers.
The accord is exclusive in under 150-bed hospitals in 48 US states and non-exclusive in the physician office lab market.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia